Annals of the Russian academy of medical sciencesAnnals of the Russian academy of medical sciencesВестник Российской академии медицинских наук0869-60472414-3545"Paediatrician" Publishers LLC22010.15690/vramn.v68i1.533PSYCHOLOGY AND PSYCHIATRY: CURRENT ISSUESАКТУАЛЬНЫЕ ВОПРОСЫ ПСИХОЛОГИИ И ПСИХИАТРИИCEREBROLYSIN FOR ACUTE ISCHEMIC STROKEЦЕРЕБРОЛИЗИН В ЛЕЧЕНИИ ОСТРОГО ИШЕМИЧЕСКОГО ИНСУЛЬТАZiganshinaL. Е.ЗиганшинаЛ. Е.
Russian Federation

PhD, Professor, Head of the Department of Fundamental and Clinical Pharmacology Address: 420008, Kazan, Kremlin St., 18; tel.: (843) 233-73-07

lezign@gmail.comAbakumovaT. R.АбакумоваТ. Р.
Russian Federation

PhD, Associate Professor of the Department of Fundamental and Clinical Pharmacology Address: 420008, Kazan, Kremlin St., 18; tel.: (843) 233-73-07

abakumovatarud@mail.ruKazan (Volga Region) Federal University, Kazan, the Republic of Tatarstan, Russian FederationКазанский (Приволжский) федеральный университет, Республика Татарстан, Российская Федерация22012013681Vestnik Rossiiskoi akademii medetsinskikh nauk / Annals of the Russian academy of medical sciencesВестник Российской академии медицинских наук212907082015Copyright ©; 1970, "Paediatrician" Publishers LLCCopyright ©; 1970, Издательство "Педиатръ"1970"Paediatrician" Publishers LLCИздательство "Педиатръ"https://vestnikramn.spr-journal.ru/jour/article/view/220

The review discusses existing evidence of benefits and risks of cerebrolysin ― a mixture of low-molecular-weight peptides and amino acids derived from pigs’ brain tissue with proposed neuroprotective and neurotrophic properties, for acute ischemic stroke. The review presents results of systematic search and analysis of randomised clinical trials comparing cerebrolysin with placebo in patients with acute ischemic stroke. Only one trial was selected as meeting quality criteria. No difference in death and adverse events between cerebrolysin and placebo was established. The authors conclude about insufficiency of evidence to evaluate the effect of cerebrolysin on survival and dependency in people with acute ischemic stroke.

В обзоре обсуждаются существующие доказательства пользы и рисков применения церебролизина ― смеси низкомолекулярных пептидов и аминокислот, полученных из мозговой ткани свиней, с заявленными нейропротективными и нейротрофическими свойствами для лечения острого ишемического инсульта. Авторами проведен систематический поиск и анализ рандомизированных контролируемых клинических испытаний, сравнивающих церебролизин с плацебо у пациентов с острым ишемическим инсультом. На основании критического анализа и оценки пригодности для систематического рассмотрения авторами выбрано единственное исследование, удовлетворяющее критериям качества. Показано отсутствие различий между церебролизином и плацебо по влиянию на смерть и неблагоприятные события. Обоснован вывод об отсутствии достаточных доказательств влияния церебролизина на выживаемость и инвалидизацию при остром ишемическом инсульте.

amino acidsneuroprotective agentsstrokeаминокислотынейропротекторыинсульт1. AHA. American Heart Association. Heart and Stroke Disease Statistics. 2007. Available at: http://www.xmarks.com/site/www.americanheart.org/presenter.jhtml%3Fidentifier=30034992. Bonita R Epidemiology of stroke. Lancet.1992; 339: 342–344.3. Bonita R., Stewart A., Beaglehole R. International trends in stroke mortality: 1970–1985. Stroke.1990; 21: 989–992.4. French B., Forster A., Langhorne P. et al. Repetitive task training for improving functional ability after stroke. Cochr. Database of Syst. Rev. 2006; (3).5. World Health Organization. The Atlas of Heart Disease and Stroke. 2007. Available at: http://www.who.int/cardiovascular diseases/resources/atlas/en/6. Gusev E.I., Skvortsova V.I., Stakhovskaia L.V. Epidemiology of stroke in Russia. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova = S.S. Korsakov journal of neurology and psychiatry. 2003; 8: 4–9.7. Vilenskii B.S., Iakhno N.N. The problem of cerebral stroke: Its contemporary state. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk = Annaols of the Russian Academy of medical Sciences. 2006; 9–10: 18–24.8. Sandercock P.A.G., Counsell C., Gubitz G.J., Tseng M.C. Antiplatelet therapy for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2008; (3).9. Wardlaw J.M., Murray V., Berge E., Zoppo G.J. et al. Thrombolysis for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2009; (4).10. Mielke M., Wardlaw J., Liu M. Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2004; (4).11. Righetti E., Celani M.G., Cantisani T. et al. Glycerol for acute stroke. Cochr. Database of Syst. Rev. 2004; (2).12. Liu M., Counsell C., Zhao X.L., Wardlaw J. Fibrinogen depleting agents for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2003; (3).13. Tirilazad International Steering Committee. Tirilazad for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2001; (4).14. Gandolfo C., Sandercock P., Conti M. Lubeluzole for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2002; (1).15. Horn J., Limburg M. Calcium antagonists for acute ischemic stroke. Cochr. Database of Syst. Rev. 2000; (1).16. Asplund K. Haemodilution for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2002; (4).17. Muir K.W., Lees K.R. Excitatory amino acid antagonists for acute stroke. Cochr. Database of Syst. Rev. 2003; (3).18. Gubitz G., Sandercock P., Counsell C. Anticoagulants for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2004; (3).19. Berge E., Sandercock P. Anticoagulants versus antiplatelet agents for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2002; (4).20. Ricci S., Celani M.G., Cantisani A.T., Righetti E. Piracetam for acute ischaemic strokе. Cochr. Database of Syst. Rev. 2006; (2).21. Shuaib A., Lees K.R., Lyden P. et al. NXY-059 for the treatment of acute ischemic stroke. N. Engl. J. Med. 2007; 357(6): 562–571.22. Ciccone A., Santilli I. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2006; (4).23. Zeng X., Liu M., Yang Y. et al. Ginkgo biloba for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2005; (4).24. Leonardi-Bee J., Steiner T., Bath-Hextall F. Naftidrofuryl for acute stroke. Cochr. Database of Syst.Rev. 2007; (2).25. Sandercock P., Counsell C., Tseng M.C. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin foracute ischaemic stroke. Cochr. Database of Syst. Rev. 2008; (3).26. Bath P.M.W., Bath-Hextall F.J. Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2004; (3).27. Bath P.M.W. Theophylline, aminophylline, caffeine and analogues for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2004; (3).28. Bereczki D., Fekete I., Prado G.F., Liu M. Mannitol for acute stroke. Cochr. Database of Syst. Rev.2 007; (3).29. Bath P.M.W., Willmot M., Leonardi-Bee J., Bath-Hextall F.J. Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke. Cochr. Database of Syst. Rev. 2002; (4).30. Blood Pressure in Acute Stroke Collaboration (BASC). Vasoactive drugs for acute stroke. Cochr. Database of Syst. Rev. 2000; (4).31. Blood Pressure in Acute Stroke Collaboration (BASC). Interventions for deliberately altering blood pressure in acute stroke. Cochr. Database of Syst. Rev. 2001; (3).32. Bath P.M.W. Prostacyclin and analogues for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2004; (3).33. Bereczki D., Fekete I. Vinpocetine for acute ischaemic stroke. Cochr. Database of Syst. Rev.1 997; (4).34. Qizilbash N., Lewington S.L., Lopez-Arrieta J.M. Corticosteroids for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2002; (3).35. Candelise L., Ciccone A. Gangliosides for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2001; (4).36. Alvarez X.A., Lombardi V.R., Corzo L. et al. Oral cerebrolysin enhances brain alpha activity and improves cognitive performance in elderly control subjects. J. Neur. Transmission.2000; 59 (Suppl.): 315–328.37. Fragoso Y., Dantas D.C. Cerebrolysin for Alzheimer’s disease. Cochr. Database of Syst. Rev. 2002; (3).38. Schauer E., Wronski R., Patockova J. et al. Neuroprotection of cerebrolysin in tissue culture models of brain ischemia: Post lesion application indicates a wide therapeutic window. J. Neur. Transmission. 2006; 113 (7): 855–868.39. Riley C., Hutter-Paier B., Windisch M. et al. A peptide preparation protects cells in organotypic brain slices against cell death after glutamate intoxication. J. Neur. Transmission. 2006; 113 (1): 103–110.40. Makarenko A.N., Kositsin N.S., Nazimov I.V. et al. A comparative study of antistroke activity of the new drug «cerebral» and its fractions in rats. Eksperimental’naia i Klinicheskaia Farmakologiia = Exp. and Clin. Pharm. 2005; 68 (2): 15–20.41. Sapronov N.S., Bul’on V.V., Kuznetsova N.N., Selina E.N. The neuroprotector effect of a new taurine derivative on a model of compression spinal cord trauma in rats. Eksperimental’naia i Klinicheskaia Farmakologiia = Exp. and Clin. Pharm. 2005; 68 (6): 45–48.42. European Ad Hoc Consensus Group. Neuroprotection as initial therapy in acute stroke, Third report of an Ad Hoc Consensus Group Meeting. Cerebrovasc. Dis. 2008; 8: 59–72.43. Wahlgren N.G., Ahmed N. Neuroprotection in cerebral ischaemia: Facts and fancies ― the need for new approaches. Cerebrovasc. Dis. 2004; 17 (Suppl. 1): 153–166.44. Chukanova E.L. The effect of cerebrolysin on the clinical symptoms and the course of ischemic encephalopathy. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova = S.S. Korsakov journal of neurology and psychiatry. 2005; 105 (1): 42–45.45. Gromova O.A., Tret’iakov V.E., Moshkovskii S.A. et al. An oligopep-tide membrane fraction of cerebrolysin. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova = S.S. Korsakov journal of neurology and psychiatry. 2006; 106 (7): 68–70.46. Onishchenko L.S., Gaikova O.N., Ianishevskii S.N. Changes in the focus of experimental ischemic stroke under the influence of neuroprotective drugs. Morfologiia = Morfol. 2006; 130 (6): 40–46.47. Gafurov B.G., Alikulova N.A. Clinical and pathogenetical peculiarities and treatment policy in ischemic stroke of elderly and old age. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova = S.S. Korsakov journal of neurology and psychiatry. 2004; 104 (Suppl. 11): 44–46.48. Ladurner G., Kalvach P., Moessler H. The Cerebrolysin Study Group, Neuroprotective treatment with cerebrolysin in patients with acute stroke: A randomised controlled trial. J. Neur. Transmission. 2005; 112: 415–428.49. Skvortsova V.I., Stakhovskaya L.V., Gubsky L.V. et al. A randomised,double-blind, placebo-controlled study of cerebrolysin safety and efficacy in the treatment of acute ischaemic stroke. Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova = S.S. Korsakov journal of neurology and psychiatry. 2004; 0 (11): 51–55.50. Wong G.K., Zhu X.L., Poon W.S. Beneficial effect of cerebrolysin on moderate and severe head injury patients: Result of a cohort study. Acta Neurochirurgica Supplement. 2005; 95: 59–60.51. Review Manager (RevMan) [Computer program]. The Nordic Cochrane Centre. The Cochrane Collaboration, Copenhagen. 2008. Version 5.0.52. Cuparnecu B. Efficacy of cerebrolysin in patients with ischaemic stroke of the middle cerebral artery. Pharmacol. Toxicol. 2001; 89 (Suppl. 1): 136.53. Haffner Z. Cerebrolysin in acute ischemic stroke. Stroke Trials Directory. Internet Stroke Center. 2001. Available at: www.strokecenter.org/trials/54. Haffner Z., Gmeinbauer R., Moessler H. A randomized, doubleblind, placebo-controlled trial with cerebrolysin in acute ischaemic stroke. Cerebrovasc. Dis. 2001; 11(Suppl. 4): 76.55. Hong Z., Li X.W., Chen Q.T. et al. Re-evaluation of cerebrolysin in treatment of early rehabilitation after ischemic stroke. Chinese J. New Drugs and Clin. Remed./Zhongguo Xinyao Yu Linchuang Zaz. 2002; 21 (3): 133–136.56. Hong Z., Zhu G., Chen H. The clinical efficacy of cerebrolysin in the treatment of acute ischemic stroke. Chinese J. Geriatric Heart Brain and Vessel Dis. 2005; 7 (5): 331–333.57. Jin J.B. Efficacy of treating cerebral apoplexy with xingnaojing compared with cerebrolysin, a report of 96 cases. Clin. Medicine/Lin chuang yi xue. 1999; 19 (9): 53–54.58. Kulchikov A.E., Makarenko A.N. Neuroimmunocorrective activity is a future for neuroprotective agent cerebrolysin. Int. J. Stroke. 2008; 3(Suppl. 1): 324–325.59. Kulchikov A.E., Makarenko A.N. The use of neuropeptides as neuroimmunocorrection agents in stroke induced viral complications. Int. J. Stroke. 2008; 3 (Suppl. 1): 456.60. Makarenko A.N., Kulchikov A.E. Treatment of infection complications of the acute stroke by cerebrolysin. Int. J. Stroke. 2006; 1 (Suppl. 1): 81.61. Ren J., Qiu Z., Du Z., Fan L. Effect comparison of injection disodium cytidine triphosphate and cerebrolysin in treatment of acute cerebral vascular disease. China Pharmacist.2002; 5 (1): 45–46.62. Sagatov D.R. Use of emoxepin in the treatment of ischemic stroke in young adult patients. Int. J. Stroke. 2008; 3 (Suppl. 1): 123.63. Shamalov N.A., Stakhovskaya L.V., Gubsky L.V. et al. Effects of the neuroprotective drug cerebrolysin on the infarct volume after acute ischemic stroke. Cerebrovasc. Dis. 2005; 19 (Suppl. 2): 107.64. Skvortsova V.I., Stakhovskaya L.V., Gubsky L.V. et al. Randomised,double-blind, placebo-controlled study of cerebrolysin safety and efficacy in the treatment of acute ischaemic stroke. Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova = S.S. Korsakov journal of neurology and psychiatry. 2004; 0 (11): 51–55.65. Skvortsova V.I., Shamalov N.A., Moessler H., Novak P.H. Beneficial effects of the neurotrophic drug cerebrolysin on the infarct volume after acute stroke. Cerebrovasc. Dis. 2008; 25 (Suppl. 2): 145.66. Skvortsova V.I., Shamalov N.A., Moessler H., Novak P.H. Positive impacts of the neurotrophic drug cerebrolysin on the infarct volume after acute stroke. Int. J. Stroke. 2008; 3(Suppl. 1): 137.67. Skvortsova V.I., Shamalov N.A., Stakhovskaya L.V. et al. Cerebrolysin in acute ischaemic stroke: Results of randomised, double blind, placebo-controlled study. Cerebrovasc. Dis. 2005; 19 (Suppl. 2): 76.68. Vilensky B.S., Odinak M.M., Shirokov E.A. et al. Experiencewith endolumbar application of cerebrolysin in hemispheric ischemic stroke. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova = S.S. Korsakov journal of neurology and psychiatry. 2000; 100 (11): 31–34.69. Vilensky B., Vinogradov O., Kuznetsov A. et al. Favorable influence of repeat cerebrolysin application in stroke patient rehabilitation. Int. J. Stroke. 2006; 1(Suppl. 1): 170.70. Wang H.T. The analysis of the efficacy of insulin, cerebrolysin, nitrendipine in the treatment of cerebral infarction. Practical Geriatrics.1997; 11: 135–136.71. Wu X. Urokinase therapy in acute ischemic stroke. Proceedings of the 4th Chinese Stroke Conference. China. Chengdu.1995. P. 149–150.72. Yavorskaya V.A., Bondar O.B. Clinical features of cerebrolysinum application in patients in acute period of ischemic stroke. Int. J. Stroke.2008; 3(Suppl. 1): 141.73. Zhang Q.Y., Xiong J., Wang R. Study on the effectiveness of cerebrolysin in 27 patients with cerebral infarction. Chinese J. Pharmacoepidemiology. 1994; 3 (4): 181–182.74. Moher D., Schulz K.F., Altman D.G. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet.2001; 357: 1191–1194.75. Ziganshina L.E, Abakumova T., Kuchaeva A. Cerebrolysin for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2010; (4).76. Shi Y.-M. Cerebrolysin in acute cerebral hemorrhage. Chinese J. Nerv. Ment. Dis.1990; 16(4): 228–230.77. Zhang S.H., Lu X.M. Nursing care of the patient with cerebral infarction and aphasia receiving carotid internal drug injection and early speech training. J. Nurs. Sci.1997; 12(1): 34–35.78. Zhu G.-X., Hong Z., Yao J.-L. Yu L.-Y. Double-blind and randomised placebo-controlled trial of cerebrolysin in improvement of nerve function and living ability in patientswith ischemic stroke. Chinese J. Clin. Rehabil. 2003; 7(22): 3084–3085.79. Ladurner G., Gmeinbauer R., Moessler H. Cerebrolysin in acute ischaemic stroke: A randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovasc. Dis.2001; 11: 75.80. Ladurner G. Neuroprotection in acute ischaemic stroke. Stroke. 2001; 32: 323.